semaglutide and crohn's disease Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy safety Glucagon-like peptide-1 (GLP-1) receptor agonists

Researchers also call for clinical trials that assess not only weight loss but broader outcomes such as psychological health, metabolic markers, and inflammation to fully understand KD's potential and safety in diverse populations

Eventually, client satisfaction is the most important factor in determining a companys success and growth and is the only belief on which we always work

Genetic variants in GLP-1 receptor and related pathways may influence individual responses to treatment, though genetics alone do not determine outcomes

"Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021 Jastreboff AM, et al